A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
Eli Lilly and Company
Pharmacyclics Switzerland GmbH
Takeda
Gadjah Mada University
Poitiers University Hospital
Department of Medical Services Ministry of Public Health of Thailand
Biogen
Bioaraba Health Research Institute
Shandong Provincial Hospital
University of Maryland, Baltimore
University of Texas Southwestern Medical Center
Hoffmann-La Roche
Seoul National University Hospital
Hoffmann-La Roche
Swedish Orphan Biovitrum
Federal University of Minas Gerais
Taipei Veterans General Hospital, Taiwan
Charite University, Berlin, Germany
Osaka City University
Amgen
Asociacion Espanola de Hematologia y Hemoterapia
Biogen
University of Bologna